Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6226291 | 0.80 | CHRM2 (0.44) | TDP1ALDH1A1ALOX15CYP3A4LMNA | |
| SCHEMBL24453542 | 0.79 | CACNA1F (0.43) | TDP1KCNN4MAPK1ALDH1A1ALOX15 | |
| SCHEMBL11127641 | 0.78 | KCNN4 (0.42) | TDP1KCNN4MAPK1ALDH1A1ALOX15 | |
| SCHEMBL10087158 | 0.77 | SMN1; SMN2 (0.39) | KCNN4MAPK1ALDH1A1LMNAALOX12 | |
| SCHEMBL16984373 | 0.77 | CYP2C9 (0.42) | ALDH1A1LMNACYP2D6MAPT | |
| SCHEMBL16121070 | 0.77 | LMNA (0.36) | ALDH1A1CYP3A4LMNAHSD17B10CYP1A2 | |
| SCHEMBL7503978 | 0.77 | KCNN4 (0.38) | TDP1KCNN4MAPK1ALDH1A1ALOX15 | |
| SCHEMBL5049524 | 0.77 | SLC6A4 (0.41) | TDP1KCNN4MAPK1ALDH1A1ALOX15 | |
| SCHEMBL5969931 | 0.77 | HDAC3 (0.44) | KCNN4LMNATSHRSSTR4HDAC3 | |
| Hydrochloric Acid SCHEMBL6820036 | 0.76 | HDAC3 (0.43) | KCNN4LMNATSHRSSTR4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230159545-A1 | ALKYNE-CONTAINING ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220162231-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-6921753-B2 | Purine derivatives | PFIZER INC (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040229838-A1 | Purine derivatives | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1296996-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2004-05-26 | — | — | EP | disclosed |
| US-20020032168-A1 | Purine derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229838-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | TDP1 526/4885KCNN4 2079/4885MAPK1 1538/4885 |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | TDP1 2632/4885KCNN4 474/4885MAPK1 709/4885 |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | TDP1 3171/4885KCNN4 140/4885MAPK1 1006/4885 |
| US-20020032168-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | TDP1 526/4885KCNN4 2079/4885MAPK1 1538/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | TDP1 2408/4885KCNN4 331/4885MAPK1 767/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | TDP1 1197/4885KCNN4 3848/4885MAPK1 940/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | TDP1 1553/4885KCNN4 2901/4885MAPK1 1226/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | TDP1 3248/4885KCNN4 4884/4885MAPK1 3042/4885 |
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | TDP1 4218/4885KCNN4 1090/4885MAPK1 781/4885 |
| US-20220162231-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | TDP1 2632/4885KCNN4 474/4885MAPK1 709/4885 |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | TDP1 3422/4885KCNN4 242/4885MAPK1 1514/4885 |
| US-20230159545-A1 | ALKYNE-CONTAINING ANTIVIRAL AGENTS | ACE, SARS1, ACE2 | TDP1 1553/4885KCNN4 2901/4885MAPK1 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.